Results 241 to 250 of about 262,879 (304)
Liver Stiffness Characterization of OGTLKO Mouse Model of Progressive Liver Fibrosis
Objectives O‐GlcNAcylation plays a key regulatory role in hepatic physiology, and its disruption leads to fibrosis in liver‐specific OGT knockout mice (OGTLKO), making this model valuable for studying advanced metabolic dysfunction‐associated steatohepatitis (MASH).
Gilles Renault +9 more
wiley +1 more source
Objective To investigate the value of transitional phase characteristics on Sonazoid contrast‐enhanced ultrasound (S‐CEUS) in the differential diagnosis of common focal liver lesions (FLLs). Materials and Methods This prospective multicenter study enrolled 122 participants with FLLs from 8 medical centers between December 2023 and March 2025. The study
Yunhao Luo +10 more
wiley +1 more source
Liver cirrhosis in 2021: Global Burden of Disease study. [PDF]
Duo H +10 more
europepmc +1 more source
ABSTRACT Hepatocellular carcinoma (HCC) surveillance with semi‐annual ultrasound (US) is recommended for high‐risk patients. This study investigates the impact of hepatobiliary abbreviated magnetic resonance imaging (AMRI) performed annually on the recommended US surveillance.
Jing‐Houng Wang +4 more
wiley +1 more source
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction‐associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non‐invasive biomarkers for tracking disease progression.
Szu‐Jen Wang +9 more
wiley +1 more source
Esophageal Variceal Grading and Platelet Count in Patients With Liver Cirrhosis. [PDF]
Farooq M +8 more
europepmc +1 more source
Exploring the mechanism of action of Jinqiancao granules against liver cirrhosis based on the liver-gut axis. [PDF]
Cheng FE +10 more
europepmc +1 more source
Intestinal congestion-driven gut dysbiosis: a cross-disease hemodynamic mechanism in liver cirrhosis and heart failure. [PDF]
Wang Y +8 more
europepmc +1 more source

